Sebela Pharmaceuticals Presents Phase 3 Tegoprazan Data in Erosive Esophagitis at Digestive Disease Week® (DDW) 2026

B Two oral presentations at DDW 2026 built upon previously reported topline results from the TRIUMpH-EE Phase 3 trials for tegoprazan and covered both erosive…
posteditor
posteditor
Articles: 21727

Other News